DLBCL is the most common type of non-Hodgkin lymphoma, accounting for ~25% of all lymphomas,1 and ~40% of B-cell lymphoma diagnosed worldwide.2

Icon Icon

What is Diffuse Large
B-Cell Lymphoma (DLBCL)?

What is Pediatric Acute Lymphoblastic Leukemia (pALL)?

Diffuse Large B-Cell Lymphoma (DLBCL) is a type of non-Hodgkin lymphoma that affects the cells and organs of the immune system. There are different types of DLBCL, including high-grade B-cell lymphoma and DLBCL that arise from follicular lymphoma.3

B cells, T cells and glands called lymph nodes make up the body’s immune system which protects the body from diseases.3 Sometimes, the cells
inside a lymph node can grow abnormally and become cancerous. Patients with Diffuse Large B-Cell Lymphoma (DLBCL) have abnormal (cancerous) B cells in their lymph nodes, and potentially in other parts of the body.
Symptoms of DLBCL include rapid swelling in the neck, underarms, or groin that is caused by enlarged lymph nodes.4

What is Pediatric Acute Lymphoblastic Leukemia (pALL)?

What are the treatment options for
Diffuse Large B-Cell Lymphoma (DLBCL)?

In cancer care, the treatment options, such as CAR-T cell therapy and recommendations depend on several factors, including the type of lymphoma, the stage (extent) of your disease, age and overall health. As treatment plans for Diffuse Large B-Cell Lymphoma (DLBCL) vary from patient to patient, it is essential to discuss your unique case history and symptoms with your care team.


Chemotherapy often consists of a combination of several medications which help to stop the spread of fast-growing cancer cells.6



A type of treatment where specific parts of the cancer cells is identified and blocked to prevent them from spreading.7 It is often used alone or in combination with other therapies, such as chemotherapy or radiation therapy.



Patient’s immune system is enhanced using medicines to better recognize and treat cancer cells.8 Examples include immune checkpoint inhibitors, immune system modulators, monoclonal antibodies, and T-cell therapy.

Chimeric Antigen Receptor (CAR) T-Cell Therapy

CAR-T cell therapy is a type of immunotherapy used to treat cancer with altered immune cells. These specially altered white blood cells, called T cells, are modified to find and stop the spread of cancer cells in the body.9



High-energy radiation is used to kill cancer cells. It is an important step before a bone marrow or stem cell transplant10



Impaired or diseased bone marrow is replaced with healthy cells from the patient’s own bone marrow or from a suitable donor.9

Learn more

What is CAR-T cell therapy?

Learn more about CAR-T cell therapy, an innovative form of immunotherapy for ALL and DLBCL patients whose current treatment may not be responding, or whose cancer has relapsed.

CAR-T Therapy involves altering one’s personal T cells, a type of white blood cell found in the immune system, with new chimeric antigen receptors (or CAR for short). When the CAR is combined with your T cells, the CAR-T cell therapy enhances the body’s natural ability to treat cancer with reprogrammed T cells. Thus, having the potential to cure the cancer completely with a one-time CAR-T treatment. Click on the video to learn more.


10,000+ patients worldwide have already experienced CAR-T cell
therapy treatment

since the first FDA approved therapy was made available in 2017.1213

Learn More

When to consider
CAR-T Therapy?

CAR-T cell therapy is an individualized treatment made from the body’s own T cells. However, data shows that T cell health will decline over time and result in poorer outcomes especially when additional treatments such as chemotherapy have been performed.

<strong>Potentially curative for patients<br> who are not responding well to initial treatments</strong>

Potentially curative for patients
who are not responding well to initial treatments

<strong>Harnesses the power of your own<br>  T-cells to detect and treat<br>  cancerous B cells</strong>

Harnesses the power of your own
T-cells to detect and treat
cancerous B cells

<strong>A one-time infusion treatment<br>  either with or without<br> hospitalization</strong>

A one-time infusion treatment
either with or without

Learn More
Is CAR-T Therapy  right for <br/>your loved one?

Is CAR-T Therapy right for
your loved one?

CAR-T cell therapy is a one-time, potentially curative, and innovative treatment option. CAR-T cell therapy is approved worldwide (by the FDA since 2017 and over 30 other health authorities) for patients who have certain types of leukemia and lymphoma, including Pediatric Acute Lymphoblastic Leukemia (pALL) and Diffuse Large B-cell Lymphoma (DLBCL).


  • Has relapsed (cancer initially responded to treatment, then came back or recurred)
  • Is refractory (cancer became resistant and never responded to standard treatment)

While the goal of CAR-T cell therapy is long-term recovery of cancer, it is important to note that not all patients will respond the same way.

Studies have shown that among patients diagnosed with DLBCL:17

  • ~10% of patients became refractory
  • ~30% to 40% of patients relapsed
Find support here
Is CAR-T Therapy  right for <br/>your loved one?


  1. SA, K. A. (Ed.). (2021). Diffuse Large B Cell Lymphoma. StatPearls Publishing. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557796/

  2. Susanibar-Adaniya, S., & Barta, S. K. (2021). 2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk
    stratification and management. American Journal of Hematology, 96(5), 617–629. https://doi.org/10.1002/ajh.26151

  3. Lymphoma action. (n.d.). Lymphoma Action. Retrieved March 11, 2022, from https://lymphoma-action.org.uk/types-lymphoma-non-hodgkin-lymphoma/ diffuse-large-b-cell-lymphoma

  4. Patient education: Diffuse large B cell lymphoma in adults (Beyond the Basics). (N.d.). Uptodate.Com. Retrieved March 11, 2022,1/12/LRF-Non-Hodgkin- Lymphoma_Factsheet.pdf.

  5. Treating B-cell non-Hodgkin lymphoma. (n.d.). Cancer.Org. Retrieved March 11, 2022, from https://www.cancer.org/cancer/non-hodgkin-lymphoma/ treating/b-cell-lymphoma.html

  6. Chemotherapy for acute Lymphocytic leukemia (ALL). (n.d.). Cancer.Org. Retrieved March 11, 2022, from https://www.cancer.org/cancer/acute- lymphocytic-leukemia/treating/chemotherapy.html

  7. Targeted therapy for acute Lymphocytic leukemia (ALL). (n.d.). Cancer.Org. Retrieved March 11, 2022, from https://www.cancer.org/cancer/acute- lymphocytic-leukemia/treating/targeted-therapy.html

  8. Immunotherapy for acute Lymphocytic leukemia (ALL). (n.d.). Cancer.Org. Retrieved March 18, 2022, from https://www.cancer.org/cancer/acute- lymphocytic-leukemia/treating/monoclonal-antibodies.html

  9. CAR-T cell therapy: Pioneering cancer therapy. (n.d.). Novartis. Retrieved March 11, 2022, from https://www.novartis.com/research-development/ technology-platforms/cell-therapy/car-t-cell-therapy-and-beyond/car-t-cell-therapy-pioneering-cancer-therapy

  10. Radiationtherapyforchildhoodleukemia.(n.d.).Cancer.Org.RetrievedMarch11,2022,fromhttps://www.cancer.org/cancer/leukemia-in-children/ treating/radiation.html

  11. How stem cell and bone marrow transplants are used to treat cancer. (n.d.). Cancer.Org. Retrieved March 11, 2022, from https://www.cancer.org/ treatment/treatments-and-side-effects/treatment-types/stem-cell-transplant/why-stem-cell-transplants-are-used.html

  12. Pharma,K.(2021).YescartaPatintBrochure.–extractedfromNovartisresource

  13. Novartis. (n.d.). Kymriah Patient Numbers – extracted from Novartis resource

  14. Zhang, H., Weyand, C. M., & Goronzy, J. J. (2021). Hallmarks of the aging T‐cell system. The FEBS Journal, 288(24), 7123–7142. https://doi.org/10.1111/ febs.15770

  15. Novartis. (2021). Kymriah Real-World Evidence Summary. – extracted from Novartis resource

  16. Kymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphoma. (n.d.). Novartis. Retrieved March 11, 2022, from https://www.novartis.com/news/media-releases/kymriah-tisagenlecleucel-first-class-car- t-therapy-from-novartis-receives-second-fda-approval-treat-appropriate-rr-patients-large-b-cell-lymphoma

  17. MorphoSys. (2021). Diffuse Large B-cell Lymphoma (DLBCL). Dlbclsupportsource.Com. https://www.dlbclsupportsource.com/pdf/diffuse-large-b-cell- lymphoma-guide.pdf


Disclaimer:This is global website for information on CAR-T Cell Therapy and is intended for Patients and Caregivers outside the US. The information on the site is not country specific and may contain information that is outside the approved indication in the country in which you are located.